The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase

Objective. Hypercholesterolemia- (HC-) induced endothelial dysfunction is the first step of atherogenesis, and the peroxisome proliferator-activated receptor γ (PPARγ) has been reported to attenuate atherosclerosis formation; however, the underlying mechanisms are not fully understood. The present s...

Full description

Saved in:
Bibliographic Details
Main Authors: Dapeng Zhang, Yehong Wang, Ming Yi, Suli Zhang, Ye Wu
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2020/1845969
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832566107327692800
author Dapeng Zhang
Yehong Wang
Ming Yi
Suli Zhang
Ye Wu
author_facet Dapeng Zhang
Yehong Wang
Ming Yi
Suli Zhang
Ye Wu
author_sort Dapeng Zhang
collection DOAJ
description Objective. Hypercholesterolemia- (HC-) induced endothelial dysfunction is the first step of atherogenesis, and the peroxisome proliferator-activated receptor γ (PPARγ) has been reported to attenuate atherosclerosis formation; however, the underlying mechanisms are not fully understood. The present study was designed to determine whether myeloperoxidase (MPO) mediates HC-induced endothelial dysfunction and the role of the PPARγ agonist pioglitazone (PIO) in attenuating endothelial dysfunction. Methods. Male Wistar rats were fed with normal or high cholesterol diets for 8 weeks. HC rats were randomized to receive dapsone (DDS, the MPO inhibitor) during the last 6 days or PIO for the remaining 4 weeks. Vascular endothelial function was determined by comparing vasorelaxation to ACh, an endothelium-dependent vasodilator, and SNP, an endothelium-independent vasodilator in vascular rings in vitro. The vascular MPO activity, NOx content, and cGMP level were measured by the MPO activity assay kit, NO assay kit, and cGMP RIA kit. Results. Compared with rats fed with normal diet, endothelium-dependent vasodilation, NOx content, and cGMP level were decreased, and MPO activity was increased in thoracic aortas of rats fed with HC diet. There was a negative correlation between vascular endothelial function, NOx content or cGMP level, and MPO activity. PIO obviously reduced the MPO activity, increased NOx content and cGMP level, and improved endothelium-dependent vasodilation function in HC rats, which was essentially the same as that seen with DDS. And, there was a negative correlation between vascular endothelial function, NOx content or cGMP level, and MPO activity in the HC group and the PIO intervention group. Conclusion. MPO might provoke vascular endothelial dysfunction in hypercholesterolemic rats by reducing the NO biological activity and impairing the NO/cGMP/cGK signaling pathway. PIO might inhibit vascular MPO activity and increase NO bioavailability with the net result of reversing endothelial dysfunction.
format Article
id doaj-art-00371ea7634b47559d17b173b62c3b32
institution Kabale University
issn 2090-8016
2090-0597
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Cardiology Research and Practice
spelling doaj-art-00371ea7634b47559d17b173b62c3b322025-02-03T01:05:00ZengWileyCardiology Research and Practice2090-80162090-05972020-01-01202010.1155/2020/18459691845969The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting MyeloperoxidaseDapeng Zhang0Yehong Wang1Ming Yi2Suli Zhang3Ye Wu4Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases, Capital Medical University, Beijing 100069, ChinaDepartment of Physiology, Shanxi Medical University, Taiyuan 030001, Shanxi, ChinaBeijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases, Capital Medical University, Beijing 100069, ChinaBeijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases, Capital Medical University, Beijing 100069, ChinaBeijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases, Capital Medical University, Beijing 100069, ChinaObjective. Hypercholesterolemia- (HC-) induced endothelial dysfunction is the first step of atherogenesis, and the peroxisome proliferator-activated receptor γ (PPARγ) has been reported to attenuate atherosclerosis formation; however, the underlying mechanisms are not fully understood. The present study was designed to determine whether myeloperoxidase (MPO) mediates HC-induced endothelial dysfunction and the role of the PPARγ agonist pioglitazone (PIO) in attenuating endothelial dysfunction. Methods. Male Wistar rats were fed with normal or high cholesterol diets for 8 weeks. HC rats were randomized to receive dapsone (DDS, the MPO inhibitor) during the last 6 days or PIO for the remaining 4 weeks. Vascular endothelial function was determined by comparing vasorelaxation to ACh, an endothelium-dependent vasodilator, and SNP, an endothelium-independent vasodilator in vascular rings in vitro. The vascular MPO activity, NOx content, and cGMP level were measured by the MPO activity assay kit, NO assay kit, and cGMP RIA kit. Results. Compared with rats fed with normal diet, endothelium-dependent vasodilation, NOx content, and cGMP level were decreased, and MPO activity was increased in thoracic aortas of rats fed with HC diet. There was a negative correlation between vascular endothelial function, NOx content or cGMP level, and MPO activity. PIO obviously reduced the MPO activity, increased NOx content and cGMP level, and improved endothelium-dependent vasodilation function in HC rats, which was essentially the same as that seen with DDS. And, there was a negative correlation between vascular endothelial function, NOx content or cGMP level, and MPO activity in the HC group and the PIO intervention group. Conclusion. MPO might provoke vascular endothelial dysfunction in hypercholesterolemic rats by reducing the NO biological activity and impairing the NO/cGMP/cGK signaling pathway. PIO might inhibit vascular MPO activity and increase NO bioavailability with the net result of reversing endothelial dysfunction.http://dx.doi.org/10.1155/2020/1845969
spellingShingle Dapeng Zhang
Yehong Wang
Ming Yi
Suli Zhang
Ye Wu
The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase
Cardiology Research and Practice
title The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase
title_full The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase
title_fullStr The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase
title_full_unstemmed The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase
title_short The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase
title_sort peroxisome proliferator activated receptor γ agonist pioglitazone protects vascular endothelial function in hypercholesterolemic rats by inhibiting myeloperoxidase
url http://dx.doi.org/10.1155/2020/1845969
work_keys_str_mv AT dapengzhang theperoxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT yehongwang theperoxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT mingyi theperoxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT sulizhang theperoxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT yewu theperoxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT dapengzhang peroxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT yehongwang peroxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT mingyi peroxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT sulizhang peroxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase
AT yewu peroxisomeproliferatoractivatedreceptorgagonistpioglitazoneprotectsvascularendothelialfunctioninhypercholesterolemicratsbyinhibitingmyeloperoxidase